Patrick Strollo
Pulmonary Disease · Pittsburgh, PANPI 1891760740
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), speaking fees and other — rather than concentrated in one kind of arrangement. Belluscura LLC accounts for 83.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $42,300 and has fallen 91.8% since, to $3,448 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $5623.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Belluscura LLC$103K
- Philips North America LLC$11K
- Eli Lilly$9K
- Aerin Medical Inc.$1K
- Inspire Medical Systems, Inc.$184
- Lilly USA, LLC$35
What the payments were for
- Consulting fees$72,15858%
- Speaking & faculty fees$41,44033%
- Travel & lodging$8371%
- Food & beverage$710%
- Other$9,2067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Belluscura LLC | 4 | $103,333 |
| Philips North America LLC | 5 | $10,646 |
| Eli Lilly | 3 | $8,514 |
| Aerin Medical Inc. | 1 | $1,000 |
| Inspire Medical Systems, Inc. | 8 | $184 |
| Lilly USA, LLC | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$7,825
- (3237) CA Undiv$6,906
- (4942) CoughAssist 2$2,300
- (7999) S&RC Undivided$1,440
- VIVAER STYLUS$1,000
How this compares
$123,713 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $242,810 |
| Modafinil | 15 | $7,122 |
| DuleraMometasone/Formoterol | 12 | $4,503 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,502 |
| Proair RespiclickAlbuterol Sulfate | 12 | $762 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $571 |
| Fluticasone Propionate | 31 | $296 |
| Azelastine Hcl | 23 | $259 |
| Zolpidem Tartrate | 14 | $74 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Pittsburgh
- Tariq CheemaPittsburgh$549K
- Stephen BashedaPittsburgh$455K
- Khalid MalikPittsburgh$144K
- Frank SciurbaPittsburgh$119K
- Sohini GhoshPittsburgh$112K
- Brian CarlinPittsburgh$102K
- Lewis KlinePittsburgh$99K
- Sally WenzelPittsburgh$70K
- Michael ApostolisPittsburgh$61K
- Sandeep Bansaldu Bois$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.